Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
3.900
-0.020 (-0.51%)
Nov 4, 2024, 4:00 PM EST - Market closed
Verastem Employees
Verastem had 73 employees as of December 31, 2023. The number of employees increased by 16 or 28.07% compared to the previous year.
Employees
73
Change (1Y)
16
Growth (1Y)
28.07%
Revenue / Employee
$136,986
Profits / Employee
-$1,225,904
Market Cap
156.95M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
biote | 194 |
Alpha Tau Medical | 121 |
Adverum Biotechnologies | 121 |
Lineage Cell Therapeutics | 75 |
Vigil Neuroscience | 69 |
Compugen | 68 |
Black Diamond Therapeutics | 54 |
Checkpoint Therapeutics | 23 |
VSTM News
- 4 days ago - Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer - Business Wire
- 4 days ago - Verastem Oncology to Participate in Upcoming Investor Conferences - Business Wire
- 18 days ago - Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting - Business Wire
- 26 days ago - Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting - Business Wire
- 4 weeks ago - Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 7 weeks ago - Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference - Business Wire
- 7 weeks ago - Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting - Business Wire
- 2 months ago - Verastem's Path To FDA Approval: High-Risk, High-Reward Oncology Opportunity - Seeking Alpha